NLS Pharmaceutics (NLSP) and Kadimastem announced that NLS has filed a Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission, SEC, regarding the previously announced merger between NLS and Kadimastem. The Registration Statement contains a prospectus in connection with the proposed merger transaction pursuant to the definitive agreement entered between the companies, as well as a proxy statement for the meeting of NLS shareholders related to certain approvals required in connection with the merger. As part of the share exchange process related to the merger, NLS is providing information about NLS’s securities offering to Kadimastem shareholders.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- NLS Pharmaceutics Calls Extraordinary Meeting for Major Capital Restructuring
- NLS Pharmaceutics and Kadimastem Advance Diabetes Treatment with FDA Submission
- NLS Pharmaceutics, Kadimastem submit request for FDA pre-IND meeting
- NLS Pharmaceutics Plans Capital Increase at Extraordinary Shareholders’ Meeting
- NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans